The CBU is proud to be part of the NIHR-MRC Dementia Deep and Frequent Phenotyping feasibility study for the UK Dementia Platform. The world class brain imaging facilities and expertise in magnetoencephalography (MEG) here will be used in partnership with the University of Cambridge Biomedical Research Unit in Dementia to identify brain technologies that can detect changes over months, rather than years. The aim is that these techniques will be used to accelerate clinical trials and the development of new treatments to treat – and prevent – dementia. The CBU’s James Rowe is the Cambridge lead for the study, which has six other UK sites. Read more here.